Clinical trial
Azacytidine and Valproic Acid in Patients With Advanced Cancers
NCT00496444 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00496444 |
|---|---|
| Title | Azacytidine and Valproic Acid in Patients With Advanced Cancers |
| Official title | Phase I Study of Low-Dose Hypomethylating Agent Azacitidine Combined With the Histone Deacetylase Inhibitor Valproic Acid in Patients With Advanced Cancers |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Cancers |
| Intervention type | Drug |
| Interventions | Azacitidine, Valproic Acid |
| Enrollment | 69 |
| Start date | May 1, 2005 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: